

Kasia J Lipska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2561557/publications.pdf>

Version: 2024-02-01

98
papers

4,901
citations

168829

31
h-index

111975

67
g-index

103
all docs

103
docs citations

103
times ranked

6506
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes and the WHO Model List of Essential Medicines. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 17-18.	5.5	1
2	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. <i>Endocrine</i> , 2022, 76, 349-358.	1.1	2
3	Defining Minimum Necessary Communication During Care Transitions for Patients on Antihyperglycemic Medication: Consensus of the Care Transitions Task Force of the IPRO Hypoglycemia Coalition. <i>Diabetes Therapy</i> , 2022, 13, 535-549.	1.2	0
4	Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?. <i>JAMA Internal Medicine</i> , 2022, 182, 520.	2.6	2
5	Fingerstick Glucose Monitoring in Veterans Affairs Nursing Home Residents with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 424-431.	1.3	4
6	Newly diagnosed diabetes and outcomes after acute myocardial infarction in young adults. <i>Heart</i> , 2021, 107, 657-666.	1.2	8
7	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107839.	1.2	4
8	Glucagon use by U.S. adults with type 1 and type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107882.	1.2	16
9	The Cost and Safety of Insulin in Older Adults. <i>JAMA Internal Medicine</i> , 2021, 181, 608.	2.6	1
10	Qualitative analysis of reasons for hospitalization for severe hypoglycemia among older adults with diabetes. <i>BMC Geriatrics</i> , 2021, 21, 318.	1.1	3
11	Beyond hemoglobin A1c: a videographic analysis of conversations about quality of life and treatment burden during clinical encounters for diabetes care. <i>Endocrine</i> , 2021, 73, 573-579.	1.1	3
12	Levothyroxine Use in the United States, 2008-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1402.	2.6	42
13	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. <i>Endocrine</i> , 2021, 74, 592-602.	1.1	2
14	Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021, 10, e21084.	1.6	35
15	Quality of life, burden of treatment, safety, and avoidance of future events (QBSafe) protocol: a pilot study testing an intervention to shift the paradigm of diabetes care. <i>Pilot and Feasibility Studies</i> , 2021, 7, 196.	0.5	2
16	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, .	0.9	27
17	Documentation of hypoglycemia assessment among adults with diabetes during clinical encounters in primary care and endocrinology practices. <i>Endocrine</i> , 2020, 67, 552-560.	1.1	6
18	Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. <i>JAMA Network Open</i> , 2020, 3, e2017645.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Self-care practices and needs in patients with hypertension, diabetes, or both in rural Uganda: a mixed-methods study. <i>The Lancet Global Health</i> , 2020, 8, S19.	2.9	4
20	Development and evaluation of a patient-centered quality indicator for the appropriateness of type 2 diabetes management. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001878.	1.2	4
21	Changes in Management of Type 2 Diabetes Before and After Severe Hypoglycemia. <i>Diabetes Care</i> , 2020, 43, e188-e189.	4.3	6
22	Expensive Insulin—The Epicenter of a Large, Life-Threatening Problem. <i>JAMA Internal Medicine</i> , 2020, 180, 931.	2.6	5
23	Development of a discrete choice experiment to understand patient preferences for diabetes and hypertension management in rural Uganda. <i>The Lancet Global Health</i> , 2020, 8, S22.	2.9	6
24	Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes. <i>JAMA Network Open</i> , 2020, 3, e1919099.	2.8	65
25	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
26	Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001007.	1.2	29
27	Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes. <i>JAMA Network Open</i> , 2019, 2, e1913249.	2.8	38
28	Association of Diabetes Mellitus With Health Status Outcomes in Young Women and Men After Acute Myocardial Infarction: Results From the VIRGO Study. <i>Journal of the American Heart Association</i> , 2019, 8, e010988.	1.6	15
29	Metformin for Type 2 Diabetes—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1313.	3.8	2
30	Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 1633.	2.6	28
31	Insulin Analogues for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 350.	3.8	13
32	Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial. <i>New England Journal of Medicine</i> , 2019, 380, 2266-2267.	13.9	6
33	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2305-2314.	1.8	24
34	Metformin in 2019. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1926.	3.8	270
35	Revalidation of the Hypoglycemia Risk Stratification Tool Using ICD-10 Codes. <i>Diabetes Care</i> , 2019, 42, e58-e59.	4.3	17
36	Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 25-33.	5.5	138

#	ARTICLE	IF	CITATIONS
37	Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates. <i>American Heart Journal</i> , 2019, 207, 19-26.	1.2	0
38	Cost-Related Insulin Underuse Among Patients With Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 112.	2.6	156
39	Surveillance of Hypoglycemia—Limitations of Emergency Department and Hospital Utilization Data. <i>JAMA Internal Medicine</i> , 2018, 178, 987.	2.6	52
40	Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1190-1194.	1.3	53
41	Defining Multiple Chronic Conditions for Quality Measurement. <i>Medical Care</i> , 2018, 56, 193-201.	1.1	14
42	Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 693-701.	1.2	25
43	Diabetes, Heart Disease, and Dementia: National Estimates of Functional Disability Trajectories. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 766-772.	1.3	10
44	Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 53.	3.8	64
45	Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment. <i>Current Diabetes Reports</i> , 2018, 18, 48.	1.7	30
46	Is the Over-the-Counter Availability of Human Insulin in the United States Good or Bad?. <i>JAMA Internal Medicine</i> , 2018, 178, 1157.	2.6	5
47	Effects of Physical Activity Intervention on Physical and Cognitive Function in Sedentary Adults With and Without Diabetes. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw179.	1.7	47
48	Is Hemoglobin A _{1c} the Right Outcome for Studies of Diabetes?. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1017.	3.8	76
49	Strategies to improve the affordability of insulin in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 158-159.	5.5	33
50	Human Insulin for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 23.	3.8	67
51	High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 869-873.	1.2	44
52	Metformin Use in Patients With Historical Contraindications. <i>Annals of Internal Medicine</i> , 2017, 166, 225.	2.0	7
53	Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. <i>JAMA Internal Medicine</i> , 2017, 177, 1461.	2.6	105
54	Hypoglycemia Patients and Transport by EMS in Alameda County, 2013–15. <i>Prehospital Emergency Care</i> , 2017, 21, 767-772.	1.0	22

#	ARTICLE	IF	CITATIONS
55	Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 200.	3.8	2
56	Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events. <i>Journal of General Internal Medicine</i> , 2017, 32, 1097-1105.	1.3	38
57	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. <i>Diabetes Care</i> , 2017, 40, 468-475.	4.3	249
58	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations. <i>Medical Care</i> , 2016, 54, 528-537.	1.1	15
59	The rising cost of diabetes care in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 479-480.	5.5	25
60	Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes. <i>JAMA Internal Medicine</i> , 2016, 176, 1714.	2.6	25
61	Diabetes in Older People. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 362.	3.8	3
62	Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience. <i>Circulation</i> , 2016, 134, 1405-1408.	1.6	27
63	Physicians frequently fail to de-intensify treatment in older patients with diabetes and very low haemoglobin A1c or blood pressure. <i>Evidence-Based Medicine</i> , 2016, 21, 158-158.	0.6	6
64	Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2016, 176, 969.	2.6	115
65	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 372-379.	0.9	22
66	Intensive Glycemic Control in Type 2 Diabetes Mellitus—A Balancing Act of Latent Benefit and Avoidable Harm. <i>JAMA Internal Medicine</i> , 2016, 176, 300.	2.6	19
67	Hypoglycemia as an indicator of good diabetes care. <i>BMJ, The</i> , 2016, 352, i1084.	3.0	26
68	Polypharmacy in the Aging Patient. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1034.	3.8	236
69	Global Noncommunicable Disease Research: Opportunities and Challenges. <i>Annals of Internal Medicine</i> , 2015, 163, 712-714.	2.0	13
70	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 779-787.	0.8	15
71	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 260-267.	0.9	16
72	Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. <i>JAMA Internal Medicine</i> , 2015, 175, 356.	2.6	317

#	ARTICLE	IF	CITATIONS
73	The Adherence to Medications in Diabetic Patients in Rural Kerala, India. <i>Asia-Pacific Journal of Public Health</i> , 2015, 27, NP513-NP523.	0.4	52
74	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000046.	1.2	9
75	Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000039.	1.2	48
76	Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2331.	3.8	75
77	Metformin in Patients With Type 2 Diabetes and Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2668.	3.8	474
78	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. <i>JAMA Internal Medicine</i> , 2014, 174, 1116.	2.6	324
79	The 2013 American Association of Clinical Endocrinologistsâ€™ Diabetes Mellitus Management Recommendations. <i>JAMA Internal Medicine</i> , 2014, 174, 179.	2.6	15
80	Comparing Diabetes Medications. <i>JAMA Internal Medicine</i> , 2014, 174, 317.	2.6	8
81	Improving Safety of Diabetes Mellitus Management. <i>JAMA Internal Medicine</i> , 2014, 174, 1612.	2.6	4
82	AACE Response to Viewpoint of December 9, 2013â€™Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 827.	2.6	0
83	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 466-470.e1.	1.2	58
84	Type of Î²-blocker use among patients with versus without diabetes after myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 273-279.e1.	1.2	14
85	HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3535-3542.	4.3	202
86	The Reliability and Prognosis of In-Hospital Diagnosis of Metabolic Syndrome in the Setting of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 704-708.	1.2	15
87	Elevated HbA1c and Fasting Plasma Glucose in Predicting Diabetes Incidence Among Older Adults. <i>Diabetes Care</i> , 2013, 36, 3923-3929.	4.3	40
88	Glucose Control in Older Adults With Diabetes Mellitusâ€™More Harm Than Good?. <i>JAMA Internal Medicine</i> , 2013, 173, 1306.	2.6	26
89	Glucose Variability and Mortality in Patients Hospitalized With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 550-557.	0.9	34
90	Management of blood glucose in patients with acute coronary syndromes. <i>Reviews in Cardiovascular Medicine</i> , 2012, 13, e77-88.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Management of Blood Glucose in Patients With Acute Coronary Syndromes. <i>Reviews in Cardiovascular Medicine</i> , 2012, 13, 77-88.	0.5	0
92	Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. <i>Diabetes Care</i> , 2011, 34, 1431-1437.	4.3	361
93	Switching From Rosiglitazone. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 820.	3.8	8
94	Hypoglycemia and adverse outcomes: marker or mediator?. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 132-5.	0.5	14
95	Discontinuation of Antihyperglycemic Therapy and Clinical Outcomes After Acute Myocardial Infarction in Older Patients With Diabetes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 236-242.	0.9	31
96	Identifying Dysglycemic States in Older Adults: Implications of the Emerging Use of Hemoglobin A1c. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5289-5295.	1.8	100
97	Cardiovascular risk-benefit ratio of thiazolidinediones. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 42-50.	0.8	3
98	Considerations for Generic-to-Generic Levothyroxine Switching—Reply. <i>JAMA Internal Medicine</i> , 0, , .	2.6	0